文献速递间质性肺疾病

纤维化间质性肺疾病急性加重:国际工作组报告

Acute exacerbation in fibrotic interstitial lung disease: an international working group report.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

该国际工作组报告汇总了自2016年AE-IPF报告以来关于纤维化间质性肺疾病(fILD)急性加重的最新证据,并将范围扩展至所有fILD。报告修订了AE-fILD的定义与诊断标准,提出急性呼吸恶化(ARW)的概念框架以涵盖各类急性呼吸恶化事件,并讨论了AE作为临床试验终点的考量及研究优先方向。

要点

  • AE-fILD定义为呼吸道症状或体征加重,伴弥漫性肺泡损伤(可伴机化性肺炎)的影像或病理特征。
  • ARW涵盖非弥漫性肺泡损伤所致的急性呼吸恶化,如肺水肿、支气管炎和肺炎。
  • AE-fILD致高发病率与死亡率,缺乏经证实有效的治疗干预。

核心结论

  • 修订的AE-fILD定义适用于所有fILD,并提出ARW概念框架以结构化评估急性呼吸恶化。

研究设计与样本

  • 国际工作组报告,基于综合文献综述汇总fILD急性加重的流行病学、相关与危险因素、预后及管理证据。

主要发现

  • AE在IPF和非IPF的fILD患者中均可发生,与高发病率和高死亡率相关。
  • AE-fILD定义为急性呼吸道事件,表现为呼吸道症状或体征加重,伴符合弥漫性肺泡损伤(伴或不伴机化性肺炎)的影像或病理特征。
  • ARW指fILD患者中由非弥漫性肺泡损伤原因所致的急性症状加重,如肺水肿、支气管炎和肺炎,但严重肺炎可触发AE-fILD。

关键数值与推荐

  • AE-fILD诊断需满足:急性呼吸道症状或体征加重,且影像或病理符合弥漫性肺泡损伤(伴或不伴机化性肺炎),患者为已知或新诊断的fILD。

临床怎么用

  • 采用修订的AE-fILD定义和ARW框架对fILD患者的急性呼吸恶化进行结构化临床评估。
  • 区分AE-fILD与ARW有助于识别不同病因并指导临床与研究场景下的分层管理。

局限性

  • 报告为工作组专家文件,基于文献综述,非原始研究。
  • AE-fILD缺乏经证实有效的治疗干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute exacerbations (AEs) occur both in patients with idiopathic pulmonary fibrosis (IPF) and those with non-IPF fibrotic interstitial lung disease (fILD). These events confer high morbidity and mortality, with a lack of proven effective therapeutic interventions. The objective of this state-of-the-art document is to summarize latest evidence since the 2016 International Working Group Report on AE-IPF, expanding it across the spectrum of all fILDs. A comprehensive literature review on the epidemiology, associated and risk factors, prognosis, and management of AE-fILD is summarized. In addition to revising the AE definition and diagnostic criteria for broad application across different fILDs, a conceptual framework for acute respiratory worsening (ARW) has been proposed to encompass a variety of acute respiratory deteriorations, both related and unrelated to AEs. This allows structured evaluation in both clinical and research settings. The proposed revised definition for AE-fILD is an acute respiratory event characterized by increased respiratory symptoms or signs and associated with radiologic or histologic features consistent with diffuse alveolar damage (with or without superimposed organizing pneumonia) in a patient with known or newly diagnosed fILD. On the other hand, ARW refers to a heterogeneous group of clinical events with acute symptom worsening not attributable to diffuse alveolar damage in patients with fILD, such as pulmonary edema, bronchitis, and pneumonia, although severe pneumonia can trigger AE-fILD. Additionally, we discuss considerations for inclusion of AE as a clinical trial endpoint, as well as research priorities for advancing knowledge on the pathogenic mechanisms, event prediction, risk stratification, and development of drugs and supportive treatments.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Khor YH, Luppi F, Adegunsoye A, et al. Acute exacerbation in fibrotic interstitial lung disease: an international working group report. Am J Respir Crit Care Med. 2026. PMID: 42447235. doi:10.1093/ajrccm/aamag363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。